Finerenone in Persons with Chronic Kidney Disease without Diabetes.

Finerenone slowed kidney function decline in adults with chronic kidney disease without diabetes, reducing eGFR loss by 0.7 ml/min/1.73m² per year over 32 months versus placebo.

• Why it matters: Prior finerenone benefits were established in type 2 diabetes with CKD, leaving uncertainty about whether similar kidney and cardiovascular advantages occur in people without diabetes.
• What they did: In a randomized trial of 1584 adults without diabetes (eGFR 25 to <90 and urinary albumin-to-creatinine ratio 200 to ≤3500) on renin-angiotensin system inhibitors, finerenone 10 or 20 mg daily was compared with placebo using a two-slope eGFR slope model to month 32.
• The result: The eGFR slope was -3.3 with finerenone vs -4.0 with placebo (difference 0.7; P<0.001), and kidney or cardiovascular events were lower (hazard ratio 0.77; P=0.04), with hyperkalemia more frequent (17.0% vs 13.3%).

AI summary of the abstract · may contain errors · not medical advice · read the paper.